Last reviewed · How we verify
Infiltrative treatment with CB-PRP
Infiltrative treatment with CB-PRP is a Biologic drug developed by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico. It is currently in Phase 1 development.
At a glance
| Generic name | Infiltrative treatment with CB-PRP |
|---|---|
| Sponsor | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Use of Platelet Rich Plasma from Cord Blood Vs Placebo in the Treatment of Vulvar Lichen Sclerosus (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Infiltrative treatment with CB-PRP CI brief — competitive landscape report
- Infiltrative treatment with CB-PRP updates RSS · CI watch RSS
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico portfolio CI
Frequently asked questions about Infiltrative treatment with CB-PRP
What is Infiltrative treatment with CB-PRP?
Infiltrative treatment with CB-PRP is a Biologic drug developed by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico.
Who makes Infiltrative treatment with CB-PRP?
Infiltrative treatment with CB-PRP is developed by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (see full Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico pipeline at /company/fondazione-irccs-ca-granda-ospedale-maggiore-policlinico).
What development phase is Infiltrative treatment with CB-PRP in?
Infiltrative treatment with CB-PRP is in Phase 1.